Skip to Accessibility Tools Skip to Content Skip to Footer


Genvoya is a combination medication that contains elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide. It is used as a standalone antiretroviral therapy (ART) regimen for HIV-1 in adults and children who weigh at least 55 pounds (25 kg) who have never taken HIV medications before.

Individuals who have previously taken HIV medications can still take Genvoya, as long as they have no drug resistance mutations to any of the ingredients in Genvoya and have had a viral load (amount of HIV in the blood) of 50 copies per mL or less on a stable ART regimen for at least six months.

Although it is not a cure for HIV, when taken as directed, it allows for the virus to be suppressed. This prevents further transmission of HIV and allows an individual’s immune system to improve through increasing CD4 cell counts and decreasing the amount of active virus in the blood (viral load).

What are the ingredients in Genvoya?

The main ingredients in Genvoya are elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide. Elvitegravir is an integrase strand transfer inhibitor (INSTI, also known as an integrase inhibitor). Cobicistat is a CYP3A inhibitor, also referred to as a pharmacokinetic enhancer. Emtricitabine and tenofovir alafenamide are nucleoside reverse transcriptase inhibitors (NRTIs).

How does Genvoya work?

Genvoya is a combination of two NRTI medications, an integrase inhibitor, and a pharmacokinetic enhancer. NRTIs stop the reverse transcription step of the HIV life cycle. Normally, HIV uses its reverse transcriptase enzyme to build a strand of DNA from its original RNA form. In order to do this, it uses genetic building blocks called nucleosides that come from the host cell. These nucleosides are strung together one at a time, like beads on a string, to create the final DNA product.

How do NRTIs work?

NRTIs act as nucleoside mimics that stop the DNA-building process. NRTIs look like normal nucleosides, except they’re missing a special chemical group on one side. Without this group, the reverse transcriptase enzyme is unable to attach more nucleosides to the chain after them. This prevents the full string of DNA from being formed, preventing HIV RNA from making it all the way through the reverse transcription process and into host DNA for further replication.

How do integrase inhibitors work?

After HIV RNA is reverse transcribed into newly-formed DNA, it gets integrated into the host cell DNA using an enzyme called integrase. This allows HIV to be actively replicated with the rest of our DNA as our cell carries out its normal functions. Integrase inhibitors can be used to block the integrase enzyme and prevent the integration of HIV DNA into our host cells. If HIV’s DNA cannot be inserted into our host cells’ genome, the virus cannot continue to be replicated, assembled into mature virus particles, and released into the blood to continue infecting other cells.

How do pharmacokinetic enhancers work?

Pharmacokinetic enhancers don’t directly target and treat HIV. Instead, they inhibit an enzyme in the human body called cytochrome P450 3A4, also called CYP3A4. Normally, CYP3A4 helps break down drugs and other molecules in the body so that they can be eliminated. Drugs that get broken down, or metabolized, by this enzyme are prevented from staying in the body for too long.

However, when CYP3A4 is inhibited by a pharmacokinetic enhancer, it allows for the normal drug targets of this enzyme to continue to exist and work in the body beyond what’s normal. By preventing the breakdown enzyme from doing its job, the concentration and efficacy of other drugs, like elvitegravir, may be increased. All three medication types work together to prevent the overall progression of HIV through its life cycle.

What are the possible side effects of Genvoya?

The most common side effects of Genvoya include, but are not limited to:

  • Nausea

Things to note about Genvoya

As with any medication, there are several very rare but serious risks that need to be considered before taking Genvoya. Your healthcare provider can help determine what issues you may be at risk for and help determine what treatment options are the safest for you. It’s also important to remember that the risk of one or more of these issues occurring is low, and the benefits of treating the virus often greatly outweigh the risks.

Several of these rare but serious side effects of Genvoya include liver issues and an increase of lactic acid in the blood (lactic acidosis). Signs of liver issues include, but are not limited to:

  • Dark-colored urine
  • Loss of appetite
  • Nausea
  • Yellowing of the whites of the eyes or skin
  • Light-colored bowel movements
  • Pain or tenderness on the right side of your stomach

Signs of lactic acidosis include, but are not limited to:

  • Trouble breathing
  • Feeling cold, especially in the limbs
  • Dizziness or lightheadedness
  • Feeling tired or weak
  • Muscle pain
  • Nausea and vomiting
  • Irregular or fast heartbeat

If you have hepatitis B virus and start taking Genvoya, your hepatitis B may get worse. There are many medications that can interact with Genvoya and cause serious issues. It’s important to tell your healthcare provider about any medications you are currently taking, have recently taken, or plan to start taking.

Rarely, Genvoya may also cause new or worsening kidney issues. This includes an increased risk of kidney failure. Your healthcare provider will need to monitor your kidney function before you start and while taking Genvoya.

Before starting Genvoya, tell your doctor if you:

  • Have or previously had hepatitis B virus
  • Have a history of liver or kidney problems
  • Are pregnant or planning to become pregnant
  • Are breastfeeding or planning to breastfeed
  • Are taking any over-the-counter vitamins, supplements, medicines, or herbal remedies
  • Are on any other medications or are about to start any other medications, including hormonal birth control or medications for hepatitis viruses

Genvoya may cause a condition called IRIS (immune reconstitution inflammatory syndrome). IRIS occurs when an individual’s immune system gets stronger after being weak and responds aggressively to previously hidden infections. This heightened response may make the person fighting the infection feel worse. Alert your healthcare provider immediately if you begin to have new symptoms after taking Genvoya.

Dosing information

The most common dosage of Genvoya is one tablet taken by mouth once a day. A tablet contains 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine and 10 mg of tenofovir alafenamide. It is important to take your medication exactly as prescribed, and to not stop or change your Genvoya dosage without talking to your healthcare provider first. Genvoya should be taken with food. If you miss a dose of Genvoya, take the next dose as soon as you remember; however, never take two at a time. If you take too much Genvoya, seek medical attention immediately.

If you take antacids or medicines that contain aluminum, or magnesium, your dosing schedule of Genvoya may need to be adjusted. Your dosing schedule may also need to be adjusted if you are on dialysis. Your healthcare provider will let you know what schedule you should be on based on your current medical history.1,2

Written by: Casey Hribar | Last reviewed: September 2019
  1. Genvoya. United States Department of Health and Human Services: AIDSinfo. Published December 14, 2018. Accessed July 20, 2019.
  2. Genvoya Prescribing Information. Gilead Sciences. Published February 2019. Accessed July 20, 2019.